Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $27.95 Average Target Price from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $27.95.

NTLA has been the topic of several analyst reports. Chardan Capital dropped their target price on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Wedbush reiterated a “neutral” rating and set a $7.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. HC Wainwright upped their price objective on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Citizens Jmp upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $33.00 price objective on the stock in a research note on Monday, October 6th. Finally, Guggenheim restated a “buy” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 13th.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William J. Chase acquired 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the purchase, the director directly owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 9,364 shares of company stock worth $137,674 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cyndeo Wealth Partners LLC grew its position in shares of Intellia Therapeutics by 9.3% in the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after purchasing an additional 995 shares during the last quarter. Benjamin Edwards Inc. grew its position in shares of Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares during the last quarter. HighTower Advisors LLC grew its position in shares of Intellia Therapeutics by 8.2% in the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock valued at $120,000 after purchasing an additional 1,282 shares during the last quarter. Johnson Financial Group Inc. grew its position in shares of Intellia Therapeutics by 24.8% in the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company’s stock valued at $66,000 after purchasing an additional 1,388 shares during the last quarter. Finally, Harbour Investments Inc. grew its position in shares of Intellia Therapeutics by 27.2% in the second quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock valued at $62,000 after purchasing an additional 1,419 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA opened at $24.52 on Tuesday. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $26.99. The firm has a market capitalization of $2.63 billion, a PE ratio of -5.23 and a beta of 2.37. The business’s 50-day simple moving average is $13.97 and its 200 day simple moving average is $10.81.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter in the prior year, the company posted ($1.52) earnings per share. Intellia Therapeutics’s revenue was up 104.3% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.